Pebezertinib

Pebezertinib (BLU 451) is an orally active inhibitor for EGFR. Pebezertinib exhibits the ability to penetrate the central nervous system (CNS) . Pebezertinib can be used for research about non-small cell lung cancer carrying EGFR exon 20 insertion[1].

Product Specifications

CAS Number

[2769954-39-2]

Product Name Alternative

BLU 451; LNG-451

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pebezertinib.html

Concentration

10mM

Purity

99.56

Solubility

DMSO : 116.67 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C(NC2=C(C3=CC=C(C(F)(F)F)C=C3)C=NC(NC4=CN(C)N=C4)=N2)=C1)F)C=C

Molecular Formula

C24H19F4N7O

Molecular Weight

497.45

References & Citations

[1]Zhou Y, et al., Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis. Explor Target Antitumor Ther. 2024;5 (3) :568-580.